

**CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2018**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE or SUBMISSION CLASS CODE	ESTABLISHED NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
NDA 021248	15	New Indication		CEPHALON INC	P	7/12/2017	1/12/2018	6.0
NDA 201292	14	New Patient Population		BOEHRINGER INGELHEIM	P	7/12/2017	1/12/2018	6.0
NDA 208558	1	New Indication		ASTRAZENECA PHARMACEUTICALS LP	P	8/18/2017	1/12/2018	4.8
NDA 021357	14	New Patient Population		BRACCO DIAGNOSTICS INC	S	12/21/2016	1/19/2018	13.0
NDA 021358	13	New Patient Population		BRACCO DIAGNOSTICS INC	S	12/21/2016	1/19/2018	13.0
NDA 208143	6	New Patient Population		BRACCO DIAGNOSTICS INC	S	3/24/2017	1/23/2018	10.0
NDA 019813	72	Manufacturing Change With Clinical Data		JANSSEN PHARMACEUTICALS INC	S	12/15/2016	1/24/2018	13.3
NDA 208745	1	Manufacturing Change With Clinical Data		SYNERGY PHARMACEUTICALS INC	S	3/24/2017	1/24/2018	10.1
NDA 019774	40	New Indication		FERRING PHARMACEUTICALS INC	S	3/31/2017	1/30/2018	10.0
NDA 019774	45	New Dosing Regimen		FERRING PHARMACEUTICALS INC	S	3/31/2017	1/30/2018	10.0
NDA 202022	11	New Patient Population		JANSSEN PRODUCTS LP	P	8/1/2017	2/1/2018	6.0
NDA 206494	4	New Indication		ALLERGAN SALES LLC	P	8/2/2017	2/1/2018	6.0
NDA 022180	9	New Indication		AMAG PHARMACEUTICALS INC	S	8/2/2017	2/2/2018	6.0
NDA 202379	24	New Indication		JANSSEN BIOTECH INC	P	9/14/2017	2/7/2018	4.8
NDA 210563	Orig - 2	Efficacy		PHARMACYCLICS LLC	P	8/31/2017	2/16/2018	5.6
NDA 204153	4	New Patient Population		MEDICIS PHARMACEUTICALS A DIV OF VALEANT PHARMACEUTICALS NORTH AMERICA LLC	S	4/21/2017	2/20/2018	10.0
NDA 204153	5	New Patient Population		MEDICIS PHARMACEUTICALS A DIV OF VALEANT PHARMACEUTICALS NORTH AMERICA LLC	S	6/21/2017	2/20/2018	8.0
NDA 021148	37	New Indication		NOVO NORDISK INC	S	8/25/2017	2/23/2018	6.0
NDA 021148	38	New Indication		NOVO NORDISK INC	S	8/25/2017	2/23/2018	6.0
NDA 207986	2	New Indication		OTONOMY INC	S	5/2/2017	3/2/2018	10.0
NDA 200603	29	New Patient Population		SUNOVION PHARMACEUTICALS INC	S	5/5/2017	3/5/2018	10.0
NDA 020965	15	New Indication		DUSA PHARMACEUTICALS INC	S	5/9/2017	3/6/2018	9.9
NDA 022068	27	New Patient Population		NOVARTIS PHARMACEUTICALS CORP	P	9/25/2017	3/22/2018	5.9
NDA 022023	17	New Patient Population		MERCK SHARP AND DOHME CORP	P	10/3/2017	4/3/2018	6.0
NDA 022496	9	New Indication		PACIRA PHARMACEUTICALS INC	S	10/6/2017	4/6/2018	6.0
NDA 209115	3	New Indication		CLOVIS ONCOLOGY INC	P	10/6/2017	4/6/2018	6.0
NDA 203985	13	New Indication		NOVARTIS PHARMACEUTICALS CORP	S	3/10/2017	4/10/2018	13.0
NDA 208065	8	New Indication		ASTRAZENECA PHARMACEUTICALS LP	P	10/18/2017	4/18/2018	6.0
NDA 208030	2	New Dosing Regimen		APOPHARMA INC	S	6/20/2017	4/20/2018	10.0
NDA 021908	16	New Indication		SUCAMPO PHARMA AMERICAS LLC	P	7/28/2017	4/26/2018	8.9
NDA 202611	11	New Indication		DEVELOPMENT INC	S	6/28/2017	4/27/2018	10.0
NDA 202806	8	New Indication		NOVARTIS PHARMACEUTICALS CORP	P	10/31/2017	4/30/2018	6.0
NDA 204114	7	New Indication		NOVARTIS PHARMACEUTICALS CORP	P	10/31/2017	4/30/2018	6.0
NDA 021446	35	New Patient Population		PF PRISM CV	P	11/3/2017	5/3/2018	6.0

CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals As of December 31, 2018

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

NDA 022488	13	New Patient Population	PREGABALIN	PF PRISM CV	P	11/3/2017	5/3/2018	6.0
NDA 205836	5	New Patient Population		UCB INC	S	7/10/2017	5/10/2018	10.0
NDA 205838	3	New Patient Population		UCB INC	S	7/10/2017	5/10/2018	10.0
NDA 021882	25	Confirmatory Study		NOVARTIS PHARMACEUTICALS CORP	S	7/13/2017	5/11/2018	9.9
NDA 022527	24	New Patient Population		NOVARTIS PHARMACEUTICALS CORP	P	11/13/2017	5/11/2018	5.9
NDA 206910	6	Confirmatory Study		NOVARTIS PHARMACEUTICALS CORP	S	7/31/2017	5/11/2018	9.3
NDA 207968	1	Confirmatory Study		NOVARTIS PHARMACEUTICALS CORP	S	7/13/2017	5/11/2018	9.9
NDA 021752	55	New Patient Population		GILEAD SCIENCES INC	P	11/16/2017	5/15/2018	5.9
NDA 203214	18			PF PRISM CV	S	5/4/2017	5/30/2018	12.9
NDA 021462	51	New Indication		ELI LILLY AND CO	S	8/3/2017	6/4/2018	10.0
NDA 208573	4	Confirmatory Study		ABBVIE INC	P	12/28/2017	6/8/2018	5.3
NDA 208573	5	New Indication		ABBVIE INC	P	1/8/2018	6/8/2018	5.0
NDA 207318	3	New Dosing Regimen		ACADIA PHARMACEUTICALS INC	S	10/27/2017	6/28/2018	8.0
NDA 203255	4	New Indication		NOVARTIS PHARMACEUTICALS CORP	S	8/30/2017	6/29/2018	10.0
NDA 021462	51	New Indication		ELI LILLY AND CO	S	8/3/2017	6/4/2018	10.0
NDA 208573	4	Confirmatory Study		ABBVIE INC	P	12/28/2017	6/8/2018	5.3
NDA 208573	5	New Indication		ABBVIE INC	P	1/8/2018	6/8/2018	5.0
NDA 207318	3	New Dosing Regimen		ACADIA PHARMACEUTICALS INC	S	10/27/2017	6/28/2018	8.0
NDA 203255	4	New Indication		NOVARTIS PHARMACEUTICALS CORP	S	8/30/2017	6/29/2018	10.0
NDA 203415	14	New Indication		ASTELLAS PHARMA US INC	P	1/16/2018	7/13/2018	5.9
NDA 022187	24	New Patient Population		JANSSEN PRODUCTS LP	P	1/16/2018	7/16/2018	6.0
NDA 209092	1	New Indication		NOVARTIS PHARMACEUTICALS CORP	P	6/28/2018	7/18/2018	0.7
NDA 019774	48	New Indication		FERRING PHARMACEUTICALS INC	S	10/3/2017	7/19/2018	9.5
NDA 019774	49	New Indication		FERRING PHARMACEUTICALS INC	S	10/3/2017	7/19/2018	9.5
NDA 019774	50	New Indication		FERRING PHARMACEUTICALS INC	S	10/3/2017	7/19/2018	9.5
NDA 019774	51	New Indication		FERRING PHARMACEUTICALS INC	S	10/3/2017	7/19/2018	9.5
NDA 202872	2	New Patient Population		BAUSCH AND LOMB INC	S	10/10/2017	7/20/2018	9.3
NDA 204427	6			ANACOR PHARMACEUTICALS INC	P	2/2/2018	7/30/2018	5.9
NDA 205223	2	New Patient Population		CHEMO RESEARCH SL	P	2/5/2018	8/3/2018	5.9
NDA 209394	2	New Patient Population		ABBVIE INC	S	10/31/2017	8/6/2018	9.2
NDA 050682	33	New Dosing Regimen		RECORDATI RARE DISEASES INC	S	10/20/2017	8/15/2018	9.8
NDA 050682	34	New Dosing Regimen		RECORDATI RARE DISEASES INC	S	10/20/2017	8/15/2018	9.8
NDA 206947	7	New Indication		EISAI INC	S	7/24/2017	8/15/2018	12.7
NDA 022038	4	New Dosing Regimen		VERTICAL PHARMACEUTICALS LLC	S	10/31/2017	8/17/2018	9.5
NDA 210563	1	New Dosing Regimen		PHARMACYCLICS LLC	P	5/30/2018	8/24/2018	2.8
NDA 021292	4	Comparative Efficacy Claim		PROVELL PHARMACEUTICALS LLC	S	3/15/2018	9/14/2018	6.0
NDA 021807	5	New Dosing Regimen		MIDATECH PHARMA US INC	S	12/1/2017	9/25/2018	9.8
NDA 202834	14	New Patient Population		EISAI INC	P	3/28/2018	9/27/2018	6.0
NDA 207534	3	New Patient Population		ADAMIS PHARMACEUTICALS CORP	S	11/27/2017	9/27/2018	10.0
NDA 208277	2	New Patient Population		EISAI INC	P	3/28/2018	9/27/2018	6.0
NDA 202714	21	New Dosing Regimen		OWNED SUB OF AMGEN INC	P	8/24/2018	9/28/2018	1.2
NDA 202439	25	New Indication		JANSSEN PHARMACEUTICALS INC	S	12/8/2017	10/11/2018	10.1
NDA 204447	17	Comparative Efficacy Claim		TAKEDA PHARMACEUTICALS USA INC	S	12/21/2017	10/19/2018	9.9
NDA 206321	7			NOVO NORDISK INC	S	12/20/2017	10/19/2018	10.0
NDA 208147	5	New Patient Population		TRIS PHARMA INC	S	9/25/2017	10/25/2018	13.0
NDA 021196	30	New Patient Population		JAZZ PHARMACEUTICALS	P	4/27/2018	10/26/2018	6.0
NDA 204042	27	New Indication		JANSSEN PHARMACEUTICALS INC	S	9/29/2017	10/29/2018	13.0

**CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2018**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

NDA 204353	25	New Indication		JANSSEN PHARMACEUTICALS INC	S	9/29/2017	10/29/2018	13.0
NDA 205879	7	New Indication		JANSSEN PHARMACEUTICALS INC	S	9/29/2017	10/29/2018	13.0
NDA 202123	29	New Patient Population		GILEAD SCIENCES INC	S	3/9/2018	10/31/2018	7.8
NDA 208351	6	New Patient Population		GILEAD SCIENCES INC	S	3/9/2018	10/31/2018	7.8
NDA 022187	23	New Patient Population		JANSSEN PRODUCTS LP	S	1/12/2018	11/6/2018	9.8
NDA 022291	21	New Indication		NOVARTIS PHARMACEUTICALS CORP	P	3/29/2018	11/16/2018	7.6
NDA 208573	9	New Indication		ABBVIE INC	P	6/25/2018	11/21/2018	4.9
NDA 204096	5	New Patient Population		ASTELLAS PHARMA US INC	S	11/1/2017	11/29/2018	12.9
NDA 208109	1	New Patient Population		FRESENIUS KABI USA LLC	S	2/8/2018	12/6/2018	9.9
NDA 209449	5	New Dosing Regimen		CYCLE PHARMACEUTICALS LTD	S	2/6/2018	12/6/2018	10.0
NDA 207561	18	New Patient Population		GILEAD SCIENCES INC	S	2/16/2018	12/10/2018	9.8
NDA 021356	57	New Patient Population		GILEAD SCIENCES INC	P	6/14/2018	12/11/2018	5.9
NDA 022577	13	New Patient Population		GILEAD SCIENCES INC	P	6/14/2018	12/11/2018	5.9
NDA 202810	10	New Patient Population		SUPERNUS PHARMACEUTICALS INC	S	2/13/2018	12/13/2018	10.0
NDA 206406	7	New Indication		VELOXIS PHARMACEUTICALS INC	S	3/7/2018	12/19/2018	9.4
NDA 208558	6	New Indication		ASTRAZENECA PHARMACEUTICALS LP	P	9/10/2018	12/19/2018	3.3
NDA 021986	21	New Indication		BRISTOL MYERS SQUIBB CO	P	6/29/2018	12/21/2018	5.8

NDA Efficacy Supplements Approved (SE8)

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE or SUBMISSION CLASS CODE	ESTABLISHED NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
NDA 205879	2	Labeling Change With Clinical Data		JANSSEN PHARMACEUTICALS INC	S	3/2/2017	1/2/2018	10.1
NDA 204819	11	Labeling Change With Clinical Data		BAYER HEALTHCARE PHARMACEUTICALS INC	S	3/15/2017	1/11/2018	9.9
NDA 202714	17	Labeling Change With Clinical Data		ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC	S	6/30/2017	1/17/2018	6.6
NDA 022522	9	Labeling Change With Clinical Data		ASTRAZENECA PHARMACEUTICALS LP	S	3/24/2017	1/23/2018	10.0
NDA 206038	7	Labeling Change With Clinical Data		VERTEX PHARMACEUTICALS INC	S	4/14/2017	1/25/2018	9.4
NDA 203565	5	Labeling Change With Clinical Data		LUITPOLD PHARMACEUTICALS INC	P	7/28/2017	1/26/2018	6.0
NDA 206192	2	Labeling Change With Clinical Data		GENENTECH INC	S	3/27/2017	1/26/2018	10.0
NDA 021992	42	Labeling Change With Clinical Data		WYETH PHARMACEUTICALS INC	S	9/17/2015	2/6/2018	28.7
NDA 021992	42	Labeling Change With Clinical Data		WYETH PHARMACEUTICALS INC	S	4/6/2017	2/6/2018	10.1
NDA 207103	7	Labeling Change With Clinical Data		PFIZER INC	S	6/20/2017	2/6/2018	7.6

**CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2018**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

NDA 021524	12	Labeling Change With Clinical Data	CHLORHEXIDINE GLUCONATE AND ISOPROPYL ALCOHOL	PROFESSIONAL DISPOSABLES INC	S	8/14/2017	2/14/2018	6.0
NDA 021945	12	Labeling Change With Clinical Data		AMAG PHARMA USA INC	S	4/14/2017	2/14/2018	10.1
NDA 021368	30	Labeling Change With Clinical Data		ELI LILLY AND CO	P	8/21/2017	2/15/2018	5.9
NDA 022555	5	Labeling Change With Clinical Data		PHOTOCURE ASA	P	8/15/2017	2/15/2018	6.0
NDA 022145	38	Labeling Change With Clinical Data		MERCK SHARP AND DOHME CORP	S	8/17/2017	3/5/2018	6.6
NDA 203314	8	Labeling Change With Clinical Data		NOVO NORDISK INC	S	5/26/2017	3/26/2018	10.0
NDA 208143	7	Labeling Change With Clinical Data		BRACCO DIAGNOSTICS INC	S	5/26/2017	3/26/2018	10.0
NDA 022200	26	Labeling Change With Clinical Data		ASTRAZENECA AB	S	6/2/2017	4/2/2018	10.0
NDA 022334	40	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	S	3/10/2017	4/10/2018	13.0
NDA 010721	61	Labeling Change With Clinical Data		CASPER PHARMA LLC	S	6/13/2017	4/13/2018	10.0
NDA 209482	1	Labeling Change With Clinical Data		GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND	S	11/21/2017	4/24/2018	5.1
NDA 204447	6	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	U	5/28/2015	5/2/2018	35.2
NDA 204447	6	Labeling Change With Clinical Data		TAKEDA PHARMACEUTICALS USA INC	U	3/22/2018	5/2/2018	1.3
NDA 205739	16	Labeling Change With Clinical Data		RELYPSA INC	S	7/27/2017	5/2/2018	9.2
NDA 202806	10	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	P	11/7/2017	5/4/2018	5.9
NDA 204114	9	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	P	11/7/2017	5/4/2018	5.9
NDA 209531	3	Labeling Change With Clinical Data		BIOGEN INC	S	7/14/2017	5/14/2018	10.0
NDA 205625	5	Labeling Change With Clinical Data		GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND	S	7/21/2017	5/17/2018	9.9
NDA 021928	45	Labeling Change With Clinical Data		PF PRISM CV	S	8/2/2017	6/1/2018	10.0
NDA 021928	46	Labeling Change With Clinical Data		PF PRISM CV	S	8/2/2017	6/1/2018	10.0
NDA 205395	9	Labeling Change With Clinical Data		JANSSEN PRODUCTS LP	P	12/14/2017	6/4/2018	5.7

**CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2018**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

NDA 202714	19	Labeling Change With Clinical Data	ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC	S	12/8/2017	6/7/2018	6.0
NDA 203085	8	Labeling Change With Clinical Data	BAYER HEALTHCARE PHARMACEUTICALS INC	S	12/21/2017	6/14/2018	5.8
NDA 020998	50	Labeling Change With Clinical Data	GD SEARLE LLC	S	6/23/2017	6/28/2018	12.2
NDA 207953	4	Labeling Change With Clinical Data	JANSSEN PRODUCTS LP	P	1/12/2018	6/29/2018	5.5
NDA 208464	4	Labeling Change With Clinical Data	GILEAD SCIENCES INC	S	10/2/2017	7/3/2018	9.0
NDA 021344	36	Labeling Change With Clinical Data	ASTRAZENECA PHARMACEUTICALS LP	S	12/21/2017	7/5/2018	6.4
NDA 021304	14	Labeling Change With Clinical Data	HOFFMANN LA ROCHE INC	S	10/5/2017	8/2/2018	9.9
NDA 022257	9	Labeling Change With Clinical Data	HOFFMANN LA ROCHE INC	S	10/5/2017	8/2/2018	9.9
NDA 202276	18	Labeling Change With Clinical Data	METUCHEN PHARMACEUTICALS LLC	S	3/5/2018	8/3/2018	5.0
NDA 019661	37	Labeling Change With Clinical Data	HOFFMANN LA ROCHE INC	S	10/23/2017	8/6/2018	9.4
NDA 203313	5	Labeling Change With Clinical Data	NOVO NORDISK INC	S	10/27/2017	8/9/2018	9.4
NDA 203314	9	Labeling Change With Clinical Data	NOVO NORDISK INC	S	10/27/2017	8/9/2018	9.4
NDA 202535	5	Labeling Change With Clinical Data	FERRING PHARMACEUTICALS INC	S	10/16/2017	8/15/2018	10.0
NDA 203188	28	Labeling Change With Clinical Data	VERTEX PHARMACEUTICALS INC	P	2/15/2018	8/15/2018	6.0
NDA 207925	7	Labeling Change With Clinical Data	VERTEX PHARMACEUTICALS INC	P	2/15/2018	8/15/2018	6.0
NDA 205552	24	Labeling Change With Clinical Data	PHARMACYCLICS LLC	P	4/9/2018	8/24/2018	4.5
NDA 205494	3	Labeling Change With Clinical Data	GENZYME CORP	S	10/31/2017	8/29/2018	9.9
NDA 208573	7	Labeling Change With Clinical Data	ABBVIE INC	P	3/8/2018	9/7/2018	6.0
NDA 208558	5	Labeling Change With Clinical Data	ASTRAZENECA PHARMACEUTICALS LP	S	4/13/2018	9/26/2018	5.5
NDA 206756	9	Labeling Change With Clinical Data	BOEHRINGER INGELHEIM PHARMACEUTICALS INC	S	12/7/2017	10/5/2018	9.9
NDA 022405	14	Labeling Change With Clinical Data	GENZYME CORP	S	12/13/2017	10/12/2018	10.0
NDA 208603	1	Labeling Change With Clinical Data	EGALET CORP	S	8/17/2018	10/12/2018	1.8

**CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2018**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

NDA 206229	7	Labeling Change With Clinical Data		MEDICINES360	S	12/15/2017	10/15/2018	10.0
NDA 020485	13	Labeling Change With Clinical Data		JOHNSON AND JOHNSON CONSUMER INC	S	12/20/2017	10/17/2018	9.9
NDA 208743	3	Labeling Change With Clinical Data		RADIUS HEALTH INC	S	12/22/2017	10/17/2018	9.8
NDA 203094	12	Labeling Change With Clinical Data		GILEAD SCIENCES INC	P	5/3/2018	10/30/2018	5.9
NDA 013684	104	Labeling Change With Clinical Data		BAXTER HEALTHCARE CORP	U	9/17/2018	11/15/2018	1.9
NDA 021003	20	Labeling Change With Clinical Data		GLAXOSMITHKLINE LLC	S	2/1/2018	11/15/2018	9.4
NDA 021004	20	Labeling Change With Clinical Data		GLAXOSMITHKLINE LLC	S	2/1/2018	11/15/2018	9.4
NDA 202570	26	Labeling Change With Clinical Data		PF PRISM CV	S	2/1/2018	11/30/2018	9.9
NDA 022059	23	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	S	2/12/2018	12/6/2018	9.8
NDA 021882	28	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	P	6/15/2018	12/12/2018	5.9
NDA 206910	9	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	P	6/15/2018	12/12/2018	5.9
NDA 207968	4	Labeling Change With Clinical Data		NOVARTIS PHARMACEUTICALS CORP	P	6/15/2018	12/12/2018	5.9
NDA 203441	12	Labeling Change With Clinical Data		NPS PHARMACEUTICALS INC	S	2/28/2018	12/18/2018	9.6
NDA 203284	10	Labeling Change With Clinical Data		HORIZON THERAPEUTICS INC	S	2/27/2018	12/21/2018	9.8
NDA 208772	4	Labeling Change With Clinical Data		ARIAD PHARMACEUTICALS INC	S	2/23/2018	12/21/2018	9.9

BLA Efficacy Supplements Approved

APPL NUMBER	SUBM TYPE & NUMBER	SUPPLEMENT TYPE	PROPER NAME	APPLICANT	PRIORITY REVIEW	RECEIPT DATE	APPROVAL DATE	TOTAL APPROVAL TIME (MONTHS)
BLA 125320	182	EFFICACY		AMGEN, INC.	S	4/3/2017	1/4/2018	9.1
BLA 125554	35	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	S	3/9/2017	1/9/2018	10.1
BLA 125554	36	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	S	3/9/2017	1/9/2018	10.1
BLA 125554	37	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	S	3/9/2017	1/9/2018	10.1
BLA 125554	38	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	S	3/9/2017	1/9/2018	10.1
BLA 125554	39	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	S	3/9/2017	1/9/2018	10.1

**CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2018**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

BLA 125349	22	EFFICACY	EMERGENT MANUFACTURING OPERATIONS BALTIMORE LLC	P	7/24/2017	1/11/2018	5.6
BLA 125504	13	EFFICACY	NOVARTIS PHARMACEUTICALS CORPORATION	S	3/23/2017	1/23/2018	10.1
BLA 125554	44	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	4/21/2017	2/15/2018	9.9
BLA 125554	45	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	4/21/2017	2/15/2018	9.9
BLA 761069	2	EFFICACY	ASTRAZENECA UK LTD	P	8/16/2017	2/16/2018	6.0
BLA 125554	48	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	5/5/2017	3/5/2018	10.0
BLA 125554	49	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	5/5/2017	3/5/2018	10.0
BLA 125554	50	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	5/5/2017	3/5/2018	10.0
BLA 125554	51	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	5/5/2017	3/5/2018	10.0
BLA 125554	52	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	5/5/2017	3/5/2018	10.0
BLA 125554	61	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	1/5/2018	3/5/2018	1.9
BLA 125554	62	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	1/5/2018	3/5/2018	1.9
BLA 125554	64	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	2/13/2018	3/5/2018	0.7
BLA 125554	65	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	2/13/2018	3/5/2018	0.7
BLA 125554	66	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	2/13/2018	3/5/2018	0.7
BLA 125388	97	EFFICACY	SEATTLE GENETICS, INC.	P	11/1/2017	3/20/2018	4.6
BLA 103362	5240	EFFICACY	SANOFI-AVENTIS U.S. LLC	P	9/29/2017	3/29/2018	6.0
BLA 125557	13	EFFICACY	AMGEN, INC.	P	9/29/2017	3/29/2018	6.0
BLA 761055	3	EFFICACY	REGENERON PHARMACEUTICALS, INC.	S	6/29/2017	4/10/2018	9.4
BLA 761025	2	EFFICACY	BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	S	6/12/2017	4/12/2018	10.0
BLA 125288	75	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	S	6/16/2017	4/13/2018	9.9
BLA 761037	1	EFFICACY	SANOFI-AVENTIS U.S. LLC	S	6/15/2017	4/13/2018	9.9
BLA 125377	94	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	P	10/16/2017	4/16/2018	6.0
BLA 125554	58	EFFICACY	BRISTOL-MYERS SQUIBB COMPANY	P	10/16/2017	4/16/2018	6.0
BLA 125085	324	EFFICACY	GENENTECH, INC.	S	11/1/2017	4/30/2018	5.9
BLA 761034	3	EFFICACY	GENENTECH, INC.	S	3/31/2017	4/30/2018	13.0
BLA 761036	13	EFFICACY	JANSSEN BIOTECH, INC.	P	11/21/2017	5/7/2018	5.5
BLA 125276	115	EFFICACY	GENENTECH, INC.	P	11/13/2017	5/11/2018	5.9
BLA 125472	28	EFFICACY	GENENTECH, INC.	P	11/14/2017	5/11/2018	5.9
BLA 125521	9	EFFICACY	ELI LILLY AND COMPANY	S	7/21/2017	5/17/2018	9.9
BLA 125320	186	EFFICACY	AMGEN, INC.	S	7/28/2017	5/18/2018	9.7
BLA 125160	283	EFFICACY	UCB, INC.	S	7/24/2017	5/25/2018	10.0
BLA 103705	5450	EFFICACY	GENENTECH, INC.	P	12/7/2017	6/7/2018	6.0
BLA 125164	78	EFFICACY	VIFOR (INTERNATIONAL) INC.	P	12/14/2017	6/7/2018	5.8
BLA 125514	34	EFFICACY	MERCK SHARP & DOHME CORP.	P	12/28/2017	6/12/2018	5.5
BLA 125085	323	EFFICACY	GENENTECH, INC.	S	8/25/2017	6/13/2018	9.6
BLA 125514	30	EFFICACY	MERCK SHARP & DOHME CORP.	P	10/3/2017	6/13/2018	8.3

**CY 2018 New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals
As of December 31, 2018**

This report reflects the data shown as it is identified in the database

Selection Criteria:

User Response: Start Date: 1/1/2018 End Date: 12/31/2018

Sort Order: Approval Date

BLA 761034	8	EFFICACY		GENENTECH, INC.	U	12/15/2017	6/14/2018	6.0
BLA 125504	5	EFFICACY		NOVARTIS PHARMACEUTICALS CORPORATION	S	12/19/2017	6/19/2018	6.0
BLA 125514	43	EFFICACY		MERCK SHARP & DOHME CORP.	P	6/6/2018	6/19/2018	0.4
BLA 761034	10	EFFICACY		GENENTECH, INC.	P	6/6/2018	6/19/2018	0.4
BLA 125469	17	EFFICACY		ELI LILLY AND COMPANY	S	8/31/2017	6/29/2018	9.9
BLA 761034	12	EFFICACY		GENENTECH, INC.	U	6/25/2018	7/2/2018	0.2
BLA 125360	73	EFFICACY		MERZ PHARMACEUTICALS GMBH C/O MERZ PHARMACEUTICALS LLC	P	1/11/2018	7/3/2018	5.7
BLA 125377	96	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	P	1/10/2018	7/10/2018	6.0
BLA 125554	63	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	P	1/10/2018	7/10/2018	6.0
BLA 125294	45	EFFICACY		SICOR BIOTECH UAB	P	1/31/2018	7/31/2018	6.0
BLA 125057	406	EFFICACY		ABBVIE INC.	S	10/2/2017	8/2/2018	10.0
BLA 125387	56	EFFICACY		REGENERON PHARMACEUTICALS, INC.	S	8/14/2018	8/16/2018	0.1
BLA 125514	46	EFFICACY		MERCK SHARP & DOHME CORP.	P	6/29/2018	8/16/2018	1.6
BLA 125554	67	EFFICACY		BRISTOL-MYERS SQUIBB COMPANY	P	2/16/2018	8/16/2018	6.0
BLA 125514	35	EFFICACY		MERCK SHARP & DOHME CORP.	P	3/23/2018	8/20/2018	4.9
BLA 125559	14	EFFICACY		SANOFI-AVENTIS U.S. LLC	S	10/24/2017	8/22/2018	9.9
BLA 103000	5308	EFFICACY		ALLERGAN, INC.	S	11/13/2017	9/12/2018	10.0
BLA 125472	31	EFFICACY		GENENTECH, INC.	P	3/12/2018	9/12/2018	6.0
BLA 103976	5231	EFFICACY		GENENTECH, INC.	P	3/29/2018	9/28/2018	6.0
BLA 125057	408	EFFICACY		ABBVIE INC.	S	12/5/2017	9/28/2018	9.8